Abcam, ab230798, Anti-AGL/Alpha-glucosidase antibody [EPR8880] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AGL/Alpha-glucosidase antibody. Carrier free. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8880,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, Flow Cyt (Intra), IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

Product details:
ab230798 is the carrier-free version of
ab133720
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Alpha-glucosidase also known as AGL is an enzyme that breaks down carbohydrates by hydrolyzing alpha-14 glycosidic bonds in glycogen converting them into glucose molecules. This enzyme is important for the body's ability to derive glucose from stored glycogen a necessary process for maintaining energy levels. AGL is predominantly expressed in liver tissue where it plays an important role in glycogen metabolism. The AGL enzyme has an approximate mass of around 104 kDa. Additionally AGL can be referred to as alpha-16-glucosidase due to its specific hydrolytic capabilities on branching points in glycogen.
Biological function summary
AGL functions as part of the glycogen debranching enzyme complex which is important for glycogen catabolism. It cooperates with other enzymes to effectively mobilize glucose from glycogen stores. AGL's debranching activity ensures the smooth continuation of glycogenolysis providing glucose to meet energy demands during fasting or intense physical activity. This highlights the enzyme's importance in glucose homeostasis and metabolic processes that require rapid energy availability.
Pathways
AGL participates in the glycogenolysis and gluconeogenesis pathways. It partners with phosphorylase to release glucose-1-phosphate from glycogen ensuring energy supply during fasting conditions. The glycogenolysis pathway relies significantly on AGL for breaking down glycogen's branched structures while glucose-6-phosphatase assists in converting glucose-6-phosphate into free glucose. AGL's role in these pathways illustrates its importance in energy metabolism and glucose regulation.
AGL's dysfunction is linked to glycogen storage disease type III known as Cori disease. This genetic disorder results from mutations in the AGL gene causing a build-up of abnormally structured glycogen in the liver and muscles leading to symptoms such as hepatomegaly muscular weakness and hypoglycemia. AGL along with other enzymes involved in glycogen metabolism like phosphorylase kinase is a target for therapeutic interventions aimed at managing such glycogen storage diseases.